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The prevalence of patent interferences in gene technology
Abstract
Unlike all other countries in the world, the United States awards patents to the first to invent, not to the
first to file an application for a patent. In cases where two or more inventors submit patent applications
claiming the same invention, an interference may be declared. Interference is the process by which the US
Patent & Trademark Office (USPTO; Washington, DC, USA) determines which of the applicants was the
first to invent and diligently reduce the invention to practice. More than half of these are resolved in favor
of the inventor who was the first-to-file, raising questions about whether this unique system is worth
retaining. Interferences are relatively rare. For the period 1998-2002, an average of four interferences were
declared for every 10,000 patent applications filed. Data we have gathered suggest that interference
proceedings in gene discovery and biotechnology are much more prevalent than other areas of
technology. The resulting legal fees are costing the biotechnology industry millions of dollars each year.
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Unlike all other countries in the world, the US awards patents to the first to invent, not to
the first to file an application for a patent. In cases where 2 or more inventors submit patent
applications claiming the same invention, an interference may be declared. Interference is the
process by which the US Patent & Trademark Office (USPTO) determines which of the
applicants was the first to invent and diligently reduce the invention to practice.
Interferences are relatively rare. For the period 1998-2002, there were an average of 4
interferences declared for every 10,000 patent applications filed. More than half of these are
resolved in favor of the inventor who was the first to file, raising questions about whether this
unique system is worth retaining.1 Despite their rarity, interferences may provide useful insights
about scientific and technological competition.
We are performing interview-based case studies on the discovery, patenting, and
commercialization of genetic inventions for a set of 7 diseases having genetic causes (Canavan
disease (CD), Chronic Myelogenous Leukemia (CML), Colon Cancers (CC), Cystic Fibrosis
(CF), Factor V Leiden (FVL), Hereditary Hemochromatosis (HH), and Spinal Muscular Atrophy
(SMA)). Our cases were chosen to capture a range of genetic diseases, encompassing rare (CD),
common (HH and CF), single gene (CD, CF, HH, FVL), multigenic (SMA, CC), and somatic
(CML) diseases. Except for CML, all of these diseases have at least one patent on a gene in
which mutations are known to be associated with disease. One has several patents on one gene
(CF), and two have patents on multiple genes (CC, SMA). Given the rarity of interferences, we
were surprised to find in this small sample that patents on the genes in 2 of these cases (CF and
FVL) had been involved in interferences.
To examine whether we were seeing evidence of a pattern, we secured from the USPTO
data on the number of interferences declared and the number of patent applications filed each
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year for FY 1998 through 2002. The data is broken down by Technology Centers (TC), which
are competency groupings within the USPTO. The number of interferences declared in each
technology field and the rate of interference declarations per 1,000 patent applications filed are
summarized in the table.
These data show that, in any one year, the rate of interference declaration involving TC
1600 (biotechnology and organic chemistry) was at least 2.5 times the rate of declaration in any
other technology area, and was about 6.5 times the average rate of all other technologies for the 5
year period (F*=63.6 with 1,7 dƒ, p<0.0001). TC 1600 encompasses drugs, herbicides,
pesticides, cosmetics, bioinformatics and other organic compounds, so this rate is not purely
attributable to biotechnologies, much less human genetics. Detailed data that would permit
greater discrimination of technology involved or historical comparisons is unavailable.
Nonetheless, staff in TC 1600 estimated that about 75% of interferences declared in the center
involve biotechnologies (George Elliott, personal communication).
These data are consistent with our observations of very high levels of competition and, in
some cases, outright races for genetic discoveries.2 Notable examples of competition in
molecular biology include the discovery of the Y chromosome in males first made by Stevens in
1905;3 the characterization of the structure of DNA;4 the hunt for HIV;5 and most recently the
quest for the sequence of the SARS virus.6 Less well-known are the close competitions for
discovery of genes for CF and familial breast and ovarian cancers, both of which involved
numerous groups. In the latter case, in the mid-1990s, multiple patents on closely related
discoveries issued to Oncormed and Myriad Genetics on BRCA1.7 Myriad and their
collaborators at the Universities of Utah and Pennsylvania similarly raced against a British and
Duke University group on BRCA2, with US patents issuing to both and potentially overlapping
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patents pending in Europe. More recently, the 2001 discovery of the gene associated with the
rare Familial Dysautonomia by 2 different research groups also may well result in an
interference, since each group filed a patent application on the gene.8,9
The high level of competition in these cases suggests several things about the nature of
the research. First, without taking any credit away from the scientists so engaged, gene
discovery has become ordinary. Necessary intellectual knowhow is shared by many, and success
is predicated upon the ability and luck in identifying, soliciting, and studying the “right” families
and groups. Second, as in other scientific fields, these discoveries build upon knowledge
contributed by others, reflecting the codependent but competitive environment of science.10
Molecular biology is data intensive, requiring the development of technologies (e.g., faster
sequencers and gene chips) and sharing of large databases. The field is relatively young, and the
rate of discovery may still be increasing. Given the large body of expertise in molecular biology
and the large volume of information now available, there may be a flood of downstream
discoveries and developments resulting from the sequencing of the human genome and a
concomitant increase in competition and the volume of interferences in the near future.
Interferences are expensive, costing an estimated $100,000 to $500,000 to resolve.1 The
biotechnology industry is strongly dependent upon patents, and the high costs of resolving
interferences are clearly seen as justified. In the 2 cases we studied, there were 3 nonprofit
research institutions and 1 firm involved, and 2 of the nonprofit institutions licensed the patent
applications to firms that bore the costs of the interferences. This is consistent with an earlier
survey of licensing and technology transfer executives in which we found that nonprofit research
institutions often seek at a minimum to cover the costs of patent prosecution in their licensing of
gene sequence patents.11
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There are several limitations to this study. First, our raw data provide no information
about the type of invention involved, and we have no ability to discriminate between cases
involving genetic discoveries (i.e., sequences and their use) compared to other biotechnology
inventions (e.g., devices). Second, our finding of a high rate of interference declaration
involving biotechnologies could be an artifact of the accuracy of computer searches by the PTO
in discovering overlapping claims for genes, but how much this might contribute to the observed
rate is unknown.
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TC

TC subject matter

FY 1998

FY 1999

FY 2000

FY 2001

FY 2002

totals

1600

Biotechnology and organic
chemistry

56 (2.1)

46 (1.5)

60 (1.8)

52 (1.4)

62 (1.5)

276 (1.6)

1700

Chemical and materials
engineering

34 (0.82)

21 (0.49)

24 (0.53)

31 (0.63)

22 (0.44)

132 (0.58)

2100

Computer architecture,
software & information
security

3 (0.076)

1 (0.034)

4 (0.058)

2600

Communications

6 (0.14)

1 (0.024)

7 (0.082)

2700

Communications and
information processing

7 (0.14)

3 (0.052)

12 (0.16)

2800

Semiconductors, electrical
& optical systems and
components

23 (0.45)

6 (0.11)

6 (0.098)

12 (0.17)

10 (0.14)

57 (0.18)

2900

Designs for articles of
manufacture

0 (0.0)

1 (0.058)

8 (0.43)

2 (0.11)

0 (0.0)

11 (0.12)

3600

Transportation,
construction, agriculture,
national security

9 (0.30)

4 (0.13)

17 (0.51)

8 (0.23)

6 (0.13)

44 (0.25)

3700

Mechanical engineering,
manufacturing, and
products

34 (0.81)

10 (0.23)

9 (0.19)

10 (0.20)

7 (0.13)

70 (0.30)

163 (0.64)

91 (0.33)

136 (0.44)

124 (0.36)

109 (0.31)

623 (0.40)

totals

22 (0.12)

Legend: Annual number of patent interferences declared in each Technology Center
field, and rate of interference declarations per 1,000 filed applications. Source: USPTO.
Note: TC 2700 was divided into Centers 2100 and 2600 at the beginning of FY2001.
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